-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2022-501780-41-00
5
2023-05-17
Irritable Bowel Syndrome
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2023-509046-36-00
5
2023-04-26
Active Ulcerative Colitis (UC) or Crohn's disease (CD)
-
2023-504897-39-00
1
2023-04-13
Advanced or refractory solid tumours (Part 1)
-
2023-508644-22-00
7
2023-02-28
Advance Solid Tumors
-
2024-515293-27-00
4
2023-02-24
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
-
2022-501181-22-01
4
2023-02-06
Pancreatic adenocarcinoma
-
2022-502140-13-00
6
2023-01-11
Atrial fibrillation
Acute coronary syndrome
Chronic coronary syndrome
-
2023-506239-14-00
5
2022-12-13
Crohn’s Disease
-
2024-514826-22-00
7
2022-12-05
Part A: Patients with advanced solid tumors or lymphomas.
-
2023-503679-12-00
1
2022-11-21
Relapsed or Refractory Multiple Myeloma
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-510990-21-00
10
2022-11-11
Mucopolysaccharidosis Type II [MPS II]
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2024-514266-39-00
7
2022-11-03
Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors wit
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2023-506517-22-00
9
2022-08-31
Advanced or Metastatic Colorectal Cancer
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-509045-13-00
5
2022-02-28
Moderately to severely active Crohn's disease (CD)
-
2024-516336-97-00
4
2022-02-21
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA